Research programme: pain therapeutics - Flexion Therapeutics

Drug Profile

Research programme: pain therapeutics - Flexion Therapeutics

Alternative Names: FX 007

Latest Information Update: 18 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca
  • Developer Flexion Therapeutics
  • Class Analgesics
  • Mechanism of Action TrkA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Musculoskeletal pain; Postoperative pain

Most Recent Events

  • 17 Apr 2018 Flexion Therapeutic terminates its licence with AstraZeneca for FX 007 in countries worldwide, effective June 2018
  • 05 Mar 2018 Flexion Therapeutics sends notice of licence termination to AstraZeneca for FX 007 in countries worldwide
  • 10 Mar 2017 Discontinued - Preclinical for Postoperative pain in USA (Intra-articular)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top